Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Research & Development: 2020-2024

Historic Research & Development for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $151.4 million.

  • NewAmsterdam Pharma Co N.V's Research & Development fell 13.25% to $31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.1 million, marking a year-over-year decrease of 12.46%. This contributed to the annual value of $151.4 million for FY2024, which is 5.03% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Research & Development stood at $151.4 million, which was down 5.03% from $159.4 million recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Research & Development registered a high of $159.4 million during FY2023, and its lowest value of $4.6 million during FY2020.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Research & Development value was $151.4 million (recorded in 2024), while the average stood at $132.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 527.35% in 2021, then fell by 5.03% in 2024.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Research & Development (Yearly) stood at $4.6 million in 2020, then soared by 527.35% to $29.0 million in 2021, then surged by 199.39% to $86.7 million in 2022, then skyrocketed by 83.79% to $159.4 million in 2023, then declined by 5.03% to $151.4 million in 2024.